Study of Axitinib for Reducing Extent of Venous Tumour Thrombus in Renal Cancer With Venous Invasion
Status:
Completed
Trial end date:
2020-06-10
Target enrollment:
Participant gender:
Summary
NAXIVA is a study of axitinib in patients with metastatic and non-metastatic renal cell
carcinoma with venous invasion. Patients will be given axitinib (twice daily) for 8 weeks (at
an escalated dose) and the response of the venous invasion will be assessed.
Blood, urine and tumour tissue samples will be taken prior to and during therapy to evaluate
biomarkers of treatment response.
The primary objective is to assess the response of the thrombus to axitinib. Its thought that
axitinib will reduce the extent of the thrombus in the inferior vena cava will reduce the
extent of surgical intervention.